The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Open accessAbstract
BACKGROUND: High plasma levels of nonfasting triglycerides are associated with an increased risk of ischemic cardiovascular disease. Whether lifelong low levels of nonfasting triglycerides owing to mutations in the gene encoding apolipoprotein C3 (APOC3) are associated with a reduced risk of ischemic cardiovascular disease in the general population is unknown. METHODS: Using data from 75,725 participants in two general-population studies, we first tested whether low levels of nonfasting triglycerides were associated with reduced risks of ischemic vascular disease and ischemic heart disease. Second, we tested whether loss-of-function mutations in APOC3, which were associated with reduced levels of nonfasting triglycerides, were also associated with reduced risks of ischemic vascular disease and ischemic heart disease. During follow-up, ischemic vascular disease developed in 10,797 participants, and ischemic heart disease developed in 7557 of these 10,797 participants. RESULTS: Participants with nonfasting triglyceride levels of less than 1.00 mmol per liter (90 mg per deciliter) had a significantly lower incidence of cardiovascular disease than those with levels of 4.00 mmol per liter (350 mg per deciliter) or more (hazard ratio for ischemic vascular disease, 0.43; 95% confidence interval [CI], 0.35 to 0.54; hazard ratio for ischemic heart disease, 0.40; 95% CI, 0.31 to 0.52). Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001). The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04). CONCLUSIONS: Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. (Funded by the European Union and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [171]
The cited source says what the claim attributes to it.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Low-density lipoprotein (LDL) cholesterol and triglyceride-rich remnant lipoproteins are causally associated with risk of atherosclerotic vascular disease [3][4][5][6]”
From APOE and vascular disease: Sequencing and genotyping in general population cohorts (2023) · cites this paper as [4]
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“Some rare heterozygous loss-of-function (LOF) variants are associated with reduced TG levels. These patients show protection from ASCVD providing important evidence for a causal role of TG for ASCVD.”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Such LOF variants of APOC3 are also associated with reduced ASCVD risk.10”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.86,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Pre-mRNA splicing and human diseasePreprint
Faustino, N. A., & Cooper, T. A. (2003) · Genes & Development · doi:10.1101/gad.1048803 · Cited by 1,248
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Self-citation
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 923
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Sundaram, M., Curtis, K. R., Alipour, M. A., LeBlond, N. D., Margison, K. D., Yaworski, R., Parks, R. J., McIntyre, A. D., Hegele, R. A., Fullerton, M. D., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m077313 · Cited by 40
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 42
Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants
Wang, H., Liu, Z., Shao, J., Jiang, M., Lu, X.-C., Lin, L., Wang, L., Xu, Q., Zhang, H. S., Li, X., et al. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.11.003 · Cited by 45
Calcaterra, I. L., Lupoli, R., Minno, A. D., & Minno, M. N. D. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13841 · Cited by 38
Musunuru, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.002 · Cited by 38
Zuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 38
Saturated hydrogen improves lipid metabolism disorders and dysbacteriosis induced by a high-fat diet
Qiu, X., Ye, Q., Sun, M., Wang, L., Tan, Y., & Wu, G. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219898407 · Cited by 37
Goyal, S., Tanigawa, Y., Zhang, W., Chai, J. F., Almeida, M., Sim, X., Lerner, M. R., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01531-8 · Cited by 40
Lipoprotein lipase regulates hematopoietic stem progenitor cell maintenance through DHA supply
Liu, C., Han, T., Stachura, D. L., Wang, H., Vaisman, B. L., Kim, J., Klemke, R. L., Remaley, A. T., Rana, T. M., Traver, D. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03775-y · Cited by 37
Effects of different weight loss approaches on CVD risk
Clifton, P. M., & Keogh, J. B. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0728-8 · Cited by 36
Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
Malick, W. A., Waksman, O., Do, R., Köenig, W., Pradhan, A. D., Stroes, E. S. G., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.034 · Cited by 38
Kim, K. A., Kim, N. J., & Choo, E. H. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad331 · Cited by 36
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 39
Christensen, A. I., Nordestgaard, B. G., & Tolstrup, J. S. (2018) · Journal of Stroke · doi:10.5853/jos.2017.01466 · Cited by 36
Self-citationTargeting angiotensinogen with RNA-based therapeutics
Ren, L., Colafella, K. M. M., Bovée, D. M., Uijl, E., & Danser, A. H. J. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000586 · Cited by 38
Reeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 40
Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies
Dib, I., Khalil, A., Chouaib, R., El-Makhour, Y., & Noureddine, H. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06071-5 · Cited by 37
Safety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
Tybjærg‐Hansen, A., Nordestgaard, B. G., & Christoffersen, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad419 · Cited by 37
Self-citationOrho‐Melander, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12407 · Cited by 39
Chan, Y., & Ramji, D. P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_1 · Cited by 41
History and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34
Secondary hypertriglyceridemia in children and adolescents
Blackett, P. R., Wilson, D. P., & McNeal, C. J. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.04.006 · Cited by 35
Targeting ApoC-III to Reduce Coronary Disease Risk
Khetarpal, S. A., Qamar, A., Millar, J. S., & Rader, D. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0609-y · Cited by 34
Personalized Management of Cardiovascular Disorders
Jain, K. K. (2017) · Medical Principles and Practice · doi:10.1159/000481403 · Cited by 37
Kegulian, N. C., Ramms, B., Horton, S. B., Trenchevska, O., Nedelkov, D., Graham, M. J., Lee, R. G., Esko, J. D., Yassine, H. N., & Gordts, P. L. S. M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312723 · Cited by 36
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 39
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 34
Aroner, S. A., Yang, M., Li, J., Furtado, J. D., Sacks, F. M., Tjønneland, A. M., Overvad, K., Cai, T., & Jensen, M. K. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx143 · Cited by 34
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
Shrestha, P., van de Sluis, B., Dullaart, R. P. F., & van den Born, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.12.001 · Cited by 34
Dietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII
Hieronimus, B., & Stanhope, K. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000653 · Cited by 33
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 40
MARAIS, D. P. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000192 · Cited by 33
CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia
Chadwick, A. C., & Musunuru, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309326 · Cited by 33
Therapeutic targets of triglyceride metabolism as informed by human genetics
Bauer, R. C., Khetarpal, S. A., Hand, N. J., & Rader, D. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.005 · Cited by 32
Multiomics in atherosclerotic cardiovascular disease
Nordestgaard, L. T., Wolford, B. N., de Gonzalo‐Calvo, D., Sopić, M., Devaux, Y., Matic, L. P., Wettinger, S. B., Schmid, J. A., Amigó, N., Masana, L., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120414 · Cited by 40
Ghafouri, K. J., Cooney, J., Bedford, D. K., Wilson, J., CASLAKE, M. J., & Gill, J. M. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1196 · Cited by 34
Nagiec, M. M., Skepner, A. P., Negri, J. M., Eichhorn, M., Kuperwasser, N., Comer, E., Muncipinto, G., Subramanian, A., Clish, C. B., Musunuru, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120295 · Cited by 31
Bays, H. E., Hallén, J., Vige, R., Fraser, D. A., Zhou, R., Hustvedt, S. O., Orloff, D. G., & Kastelein, J. J. P. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.012 · Cited by 32
Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia
Wierzbicki, A. S., & Viljoen, A. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1196182 · Cited by 32
Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease
Shu, L., Blencowe, M., & Yang, X. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00056 · Cited by 31
Yingchun, H., Ma, Y., Wen, J., He, X., & Xiaohong, Z. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0867-5 · Cited by 35
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 33
Importance of Genetic Studies of Cardiometabolic Disease in Diverse Populations
Fernández‐Rhodes, L., Young, K. L., Lilly, A. G., Raffield, L. M., Highland, H. M., Wojcik, G. L., Agler, C. S., Love, S.-A. M., Okello, S., Petty, L. E., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.315893 · Cited by 33
Kristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 33
Morton, A. M., Furtado, J. D., Lee, J., Amerine, W., Davidson, M. H., & Sacks, F. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.005 · Cited by 32
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
Leveraging human genetics to guide drug target discovery
Stitziel, N. O., & Kathiresan, S. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.08.008 · Cited by 31
Cao, Y., Zhang, H., Jin, J., Liu, H., Zhang, Y., Xu, R., Gao, Y., Guo, Y., Zhu, C., Hua, Q., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000746 · Cited by 31
Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury
Schunk, S. J., Hermann, J., Sarakpi, T., Triem, S., Lellig, M., Hahm, E., Zewinger, S., Schmit, D., Becker, E., Möllmann, J., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021040503 · Cited by 31
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
Zein, M. A., Khazzeka, A., Khoury, A. E., Zein, J. A., Dima, Z., & Eid, A. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.10.009 · Cited by 35
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 41
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 35
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 30
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 32
Rare versus common diseases: a false dichotomy in precision medicine
Chung, B. H., Chau, J. F. T., & Wong, G. K. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00176-x · Cited by 31
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Ainola, M., Hakkarainen, A., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160607 · Cited by 30
APOC3 induces endothelial dysfunction through TNF-α and JAM-1
Tao, Y., Xiong, Y.-S., Wang, H., Chu, S.-P., Zhong, R., Wang, J., Wang, G., Ren, X., & Yu, J. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0326-0 · Cited by 32
Tolstrup, J. S., Wium-Andersen, M. K., Ørsted, D. D., & Nordestgaard, B. G. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316641804 · Cited by 29
Self-citationUnderstanding Hypertriglyceridemia: Integrating Genetic Insights
Alves, M., Laranjeira, F., & Correia‐da‐Silva, G. (2024) · Genes · doi:10.3390/genes15020190 · Cited by 35
Genetic control of the mouse HDL proteome defines HDL traits, function, and heterogeneity
Pamir, N., Pan, C., Plubell, D. L., Hutchins, P. M., Tang, C., Wimberger, J., Irwin, A. D., Vallim, T. Q. D. A., Heinecke, J. W., & Lusis, A. J. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m090555 · Cited by 29
The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review
Abohelwa, M., Kopel, J. J., Shurmur, S. W., Ansari, M. M., Awasthi, S., & Awasthi, S. (2023) · Journal of Vascular Diseases · doi:10.3390/jvd2010010 · Cited by 43
The Remnants of Residual Risk∗
Joshi, P. H., Martin, S. S., & Blumenthal, R. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.543 · Cited by 29
What Causes Premature Coronary Artery Disease?
Le, A., Peng, H., Golinsky, D., Scipio, M. D., Lali, R., & Paré, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01200-y · Cited by 33
High alcohol consumption causes high IgE levels but not high risk of allergic disease
Lomholt, F. K., Nielsen, S. F., & Nordestgaard, B. G. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.022 · Cited by 28
Self-citationNatural human knockouts and the era of genotype to phenotype
Alkuraya, F. S. (2015) · Genome Medicine · doi:10.1186/s13073-015-0173-z · Cited by 28
Hu, S., Cui, G., Huang, J., Jiang, J.-G., & Wang, D. W. (2016) · Scientific Reports · doi:10.1038/srep32700 · Cited by 29
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 29
Oniciu, D. C., Hashiguchi, T., Shibazaki, Y., & Bisgaier, C. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194568 · Cited by 27
Feingold, K. R. (2015) · Europe PMC (PubMed Central) · Cited by 28
Nordestgaard, L. T., Tybjærg‐Hansen, A., Rasmussen, K. L., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2018) · BMC Medicine · doi:10.1186/s12916-018-1029-3 · Cited by 25
Self-citationAroner, S. A., Furtado, J. D., Sacks, F. M., Tsai, M. Y., Mukamal, K. J., McClelland, R. L., & Jensen, M. K. (2019) · Diabetologia · doi:10.1007/s00125-019-4847-8 · Cited by 27
RNA-based therapy in the management of lipid disorders: a review
Blom, D. J., Marais, A. D., Moodley, R., van der Merwe, N., van Tonder, A., & Raal, F. J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01649-3 · Cited by 29
Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?
Nsaibia, M. J., Devendran, A. S., Goubaa, E., Bouitbir, J., Capoulade, R., & Bouchareb, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123331 · Cited by 24
Lightbourne, M., Startzell, M. S., Bruce, K. D., Brite, B., Muniyappa, R., Skarulis, M. C., Shamburek, R. D., Gharib, A. M., Ouwerkerk, R., Walter, M. F., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.011 · Cited by 27
Spagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 27
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
Meyers, N. L., Larsson, M., Vorrsjö, E., Olivecrona, G., & SMALL, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071126 · Cited by 30
Leukocyte–endothelial interaction in CKD
Sarakpi, T., Mesic, A., & Speer, T. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad135 · Cited by 27
New approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia
Sun, B., Xie, Y., Jiang, J., Wang, Y., Xu, X., Zhao, C., & Huang, F. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0032-3 · Cited by 26
Drenos, F., Smith, G. D., Ala‐Korpela, M., Kettunen, J., Würtz, P., Soininen, P., Kangas, A. J., Dale, C. E., Lawlor, D. A., Gaunt, T. R., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001302 · Cited by 26
Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable.
Hilleman, D. E., & Smer, A. M. (2016) · PubMed · Cited by 26
Apolipoprotein CIII is a new player in diabetes
Juntti‐Berggren, L., & Berggren, P. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000372 · Cited by 27
Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk
Zhou, Y., Mägi, R., Milani, L. A., & Lauschke, V. M. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p086710 · Cited by 28
Drug development advances in human genetics‐based targets
Zhang, X., Yu, W., Li, Y., Wang, A., Cao, H., & Fu, Y. (2024) · MedComm · doi:10.1002/mco2.481 · Cited by 26
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events
Raggi, P., Becciu, M. L., & Navarese, E. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000921 · Cited by 25
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 28
Apolipoprotein E content of VLDL limits LPL-mediated triglyceride hydrolysis
Whitacre, B. E., Howles, P. N., Street, S. E., Morris, J. C., Swertfeger, D. K., & Davidson, W. S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100157 · Cited by 25
Kumari, A., Grønnemose, A. L., Kristensen, K. K., Winther, A.-M. L., Young, S. G., Jørgensen, T. J. D., & Ploug, M. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221888120 · Cited by 24
Sahebkar, A., Simental‐Mendía, L. E., Mikhailidis, D. P., Pirro, M., Banach, M., Sirtori, C. R., Ruscica, M., & Reiner, Ž. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.008 · Cited by 25
A novel system to quantify intestinal lipid digestion and transport
Sæle, Ø., Rød, K. E., Quinlivan, V. H., Li, S., & Farber, S. A. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.05.006 · Cited by 25
Volanesorsen for treatment of familial chylomicronemia syndrome
Lazarte, J., & Hegele, R. A. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955348 · Cited by 25
Greve, A. M., Wulff, A. B., Bojesen, S. E., & Nordestgaard, B. G. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae089 · Cited by 26
Self-citationGagnon, É., & Arsenault, B. J. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117501 · Cited by 23
Kraaijenhof, J. M., Kerkvliet, M., Nurmohamed, N. S., Grefhorst, A., Kroon, J., Wareham, N. J., Hovingh, G. K., Stroes, E. S. G., Boekholdt, S. M., & Reeskamp, L. F. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf037 · Cited by 28
Moens, S. J. B., van Capelleveen, J. C., & Stroes, E. S. G. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000130 · Cited by 24
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 26
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 32-41
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2052644460
- Semantic Scholar
- 55f5e169d6f4d9a568cca4bbafe0790022e8bc16
- Cited by
- 919
- References
- 39
- Citations by year
- 2026: 50 · 2025: 76 · 2024: 49 · 2023: 46 · 2022: 65 · 2021: 64 · 2020: 95 · 2019: 71 · 2018: 71 · 2017: 99 · 2016: 113 · 2015: 87 · 2014: 32
- FWCI
- 75.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Gentofte Hospital
- Rigshospitalet
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, ischemic vascular disease, ischemic heart disease, cardiovascular risk, heterozygosity, genetic variants, triglyceride lowering, general population, hypertriglyceridemia, genetic epidemiology, Mendelian randomization
- MeSH terms
- Adult, Aged, Female, Genotype, Humans, Ischemia, Cholesterol, LDL, Liver, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Incidence, Myocardial Ischemia, Sequence Analysis, DNA, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
